Catalent To Present at INTERPHEX - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catalent To Present at INTERPHEX



Catalent will recognize 80 years of softgel advancements at INTERPHEX on March 18-20, 2014 in New York City with presentations from its senior management team, as well as graduates from the company’s Global Operations Leadership Development (GOLD) program.

On Wednesday, March 19, Sridhar Krishnan, Catalent’s vice president, Global Operations, will present “Catalent GOLD - Accelerating Leadership Pipeline in Pharma & Biotech.” Catalent’s GOLD program is a two-year leadership development opportunity, designed for university graduates who have a desire to accelerate their career growth in an entrepreneurial, fast-paced environment. Krishnan’s presentation, which takes place from 10:30 to 11:30 AM, will outline the GOLD leadership model and feature the experiences of three graduates who have participated in the program.

Also on Wednesday 19, from 2:45 to 3:45 PM, Akan Oton, director, Global Licensing & CorporateAlliances, will lead a discussion on “Commercializing Emerging Drug Delivery Technologies.” His presentation will address the evolving role of drug delivery in pharma products from a commercial perspective and will look at current trends in drug delivery and unmet needs currently being pursued. He will also give examples of a typical path to commercialization of drug delivery technologies by innovators.

On Thursday, March 20, from 11:45 AM to 12:45 PM, Bill Hartzel, director, Strategic Execution, Advanced Delivery Technologies will present, “Advanced Aseptic Processing to Reduce Risk with Sterile Fill/Finish.” His presentation will feature ways to identify the QbD elements of Blow/Fill/Seal equipment and the evaluation of the risk mitigation properties of advanced aseptic properties as well astaking a look at Catalent’s newly launched ADVASEPT technology.

Source: Catalent

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here